Eli Lilly has announced plans to establish a $5 billion manufacturing facility in Virginia dedicated to antibody-drug conjugates (ADCs), signaling the company’s deeper push into advanced biologics and domestic production.
According to The Economic Times, the proposed facility will be Lilly’s first fully integrated site for both active pharmaceutical ingredients (APIs) and drug products supporting its bioconjugate platform and monoclonal antibody portfolio. ADCs, which combine targeted monoclonal antibodies with active pharmaceutical ingredients, represent a growing therapeutic class in oncology and other specialties, enabling more precise delivery of potent drugs.
The Virginia plant is part of Lilly’s broader $50 billion capital expansion program announced earlier this year, which includes four new global facilities. The site is expected to be completed within five years and will generate approximately 650 new jobs across engineering, laboratory sciences, and operations. David A. Ricks, Lilly’s chair and CEO, said the expansion would strengthen the resilience of the company’s supply chain while preparing for future demand in breakthrough therapies.
The investment comes at a time when the U.S. administration is urging pharmaceutical and biotech companies to expand domestic manufacturing capacity, citing vulnerabilities in global supply chains. Ongoing Section 232 investigations, which could result in new import tariffs on pharmaceutical products, have further reinforced the need for U.S.-based infrastructure.
Other multinational companies are also expanding their U.S. manufacturing footprints. AbbVie has committed $195 million to expand API production at its Illinois site, while Johnson & Johnson recently announced a $2 billion partnership with FUJIFILM for biologics production and indicated plans for additional advanced facilities in the U.S. These moves reflect a broader trend of reshoring critical pharmaceutical manufacturing capacity to ensure supply security and mitigate geopolitical risks.
For the global healthcare ecosystem, Lilly’s new site underlines both the increasing importance of ADCs as a therapeutic platform and the growing shift toward regionalized supply chains. While patients stand to benefit from improved reliability in access to advanced therapies, the investments also signal intensifying competition among biopharma companies to lead in complex biologics manufacturing.
As ADCs continue to gain traction in oncology and beyond, the scale of Lilly’s investment underscores how strategic manufacturing capabilities are becoming central to global competitiveness in biopharma.
